XLV, the Health Care Select Sector SPDR ETF, heads into the first week of August with short interest climbing to a one-month high even as the fund retreats from a strong July — a quiet but consistent divergence worth noting.
The short-side story has been building steadily. Short interest has risen roughly 14% over the past six weeks, from around 10.3 million shares in late June to 15.6 million shares today, lifting the SI as a percentage of free float to 6.0%. That's a meaningful level for a large sector ETF, where shorts typically express macro or sector-rotation views rather than single-stock conviction. The monthly rate of change — up nearly 10% — is the most telling signal: this isn't a one-day repositioning, it's a sustained rebuild. The ORTEX short score sits at 52.6, down slightly from a recent peak near 56 earlier in the week, suggesting the pressure is real but not yet at an extreme.
Borrow conditions are tightening, but remain manageable for now. Cost to borrow has climbed 43% on the week to 0.55%, its highest level in the 30-day window — though in absolute terms it stays firmly in "cheap to borrow" territory. The more interesting signal is availability, which tightened sharply from around 350% in mid-July to a recent low of 89% before rebounding to 172% on Tuesday. That mid-week tightening — availability briefly approaching the range where borrow can become genuinely competitive — coincided with the heaviest days of short-interest building. At 172% availability now, there's still room in the lending pool, but the directional move over the past fortnight is clearly tighter, not looser.
Options positioning reflects the same defensive tilt across the sector. The put/call ratio is running at 1.32, in line with its 20-day average of 1.31 — meaning hedging demand is elevated but not accelerating from here. The z-score of 0.31 puts current options flow squarely in the middle of its recent range. What's notable is the persistent level: XLV's PCR has traded above 1.25 for most of the past six weeks, a baseline that points to a healthcare investor base that structurally leans on protection. The 52-week PCR high is 2.67, so there's no sign of acute panic, but demand for downside protection has clearly been a consistent feature since early July.
The fund's 3.1% drop on the week, bringing it to $162.10, follows a brief July rally driven by pharma and biotech earnings beats. That backdrop makes the renewed short-building slightly counterintuitive on the surface — but sector ETF shorts often act as portfolio hedges rather than directional bets on the underlying names. JPMorgan trimmed its XLV holding by roughly 968,000 shares as of the March quarter-end, while Managed Account Advisors remains the largest holder with an 8.6% stake after adding nearly 2.9 million shares in Q1. The institutional picture is broadly stable, with most large holders showing modest reductions rather than any material exit.
What to watch next: whether the cost-to-borrow trend continues higher through the week and whether short interest crosses above the 16 million share level that would represent a multi-month high — two data points that together would indicate the sector-hedge thesis is becoming more crowded rather than simply rebuilding.
See the live data behind this article on ORTEX.
Open XLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
